The growing emphasis on advanced liver fibrosis treatments highlights a paradigm shift in addressing chronic liver diseases, ...

Fatty liver disease, or hepatic steatosis, occurs when excess fat accumulates in liver cells. Commonly associated with ...

Among the general US population, simple and affordable non-invasive liver fibrosis scoring systems may be able to identify individuals at risk for HF.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment ...

The following is a summary of “Association between the triglyceride-glucose index and liver fibrosis in adults with ...

The therapy showed a ‘favourable’ safety profile both as a single agent and in combination with standard-of-care treatment.

“Calculating FIB-4 for HCV pretreatment evaluation is simple and saves lives and money compared with requiring transient elastography or other testing approaches for liver fibrosis staging ...

Hepatic fibrosis is the common result of injury to the liver from a variety of damaging mechanisms, and the accurate assessment of the degree of fibrosis is clinically important. For many years ...

FEGATO-01 is a Phase 1b clinical trial where 41 patients with mainly advanced F3/F4 liver fibrosis and/or mild cirrhosis were dosed for up to 4 weeks (NCT05939947). “Interim results from the ...

In 2023, the United States represented the largest portion of the Liver Fibrosis market, comprising around 79% of the total market size across the 7MM, surpassing other key regions such as the EU4 ...